Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G).
about
A multi-institution phase II study of docetaxel and S-1 in combination with trastuzumab for HER2-positive advanced gastric cancer (DASH study).Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer: Preliminary results of a phase II study.
P2860
Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G).
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Five-weekly S-1 plus cisplatin ...... d biomarker study (WJOG7212G).
@en
Five-weekly S-1 plus cisplatin ...... e II trial and biomarker study
@nl
type
label
Five-weekly S-1 plus cisplatin ...... d biomarker study (WJOG7212G).
@en
Five-weekly S-1 plus cisplatin ...... e II trial and biomarker study
@nl
prefLabel
Five-weekly S-1 plus cisplatin ...... d biomarker study (WJOG7212G).
@en
Five-weekly S-1 plus cisplatin ...... e II trial and biomarker study
@nl
P2093
P2860
P1433
P1476
Five-weekly S-1 plus cisplatin ...... d biomarker study (WJOG7212G).
@en
P2093
Hiroharu Shinozaki
Hirotsugu Yoshiyama
Hiroyuki Okuda
Ichinosuke Hyodo
Katsuhiko Nosho
Katsunori Shinozaki
Kazuhiro Nishikawa
Kazuo Nishikawa
Keisei Taku
Keita Uchino
P2860
P2888
P356
10.1007/S10120-017-0725-6
P577
2017-05-11T00:00:00Z